Laboratory values by liver stiffness (groups & continuous)
LS groups: LS≤6 kPa, 6<LS≤10 kPa, LS≥10 kPa • LS continuous association shown after Overall
Variable Overall LS (continuous)
association1
Group comparison by LS categories
 p (LS) Group test2 Assumption tests Assumption results
LS≤6 kPa 6 < LS ≤ 10 kPa LS ≥ 10 kPa p value
Baseline (Labs) — Overall n=34 | group ns: 10/16/8
Hemoglobine (g/dL) 13.6 (± 1.7) Spearman ρ=-0.12; p=0.495 14.1 (± 1.8) 13.4 (± 1.5) 13.6 (± 1.8) 0.588 0.495 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.761; Levene p=0.844
Platelets (x 103/mm3) 175 (± 55) Spearman ρ=0.10; p=0.564 178 (± 49) 166 (± 51) 190 (± 74) 0.615 0.564 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.410; Levene p=0.389
Creatinine (mg/dL) 1.43 (± 1.55) Spearman ρ=-0.02; p=0.920 1.08 (± 0.34) 1.78 (± 2.21) 1.18 (± 0.47) 0.578 0.920 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.535
NT-proBNP (pg/ml) 1902 (1019-3358) Spearman ρ=-0.13; p=0.468 1872 (1030-4363) 1713 (1095-2794) 2550 (941-3204) 0.990 0.468 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.687
Alkaline Phosphatase (IU/L) 94 (± 39) Spearman ρ=0.00; p=0.987 105 (± 43) 84 (± 41) 99 (± 32) 0.439 0.987 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.405; Levene p=0.639
ALT (IU/L) 24 (± 11) Spearman ρ=0.25; p=0.149 24 (± 12) 23 (± 10) 27 (± 11) 0.633 0.149 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.002; Levene p=0.845
AST (IU/L) 28 (± 10) Spearman ρ=0.19; p=0.278 30 (± 11) 24 (± 7) 33 (± 11) 0.064 0.278 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.230; Levene p=0.330
GGT (IU/L) 78 (± 64) Spearman ρ=0.36; p=0.038 63 (± 53) 60 (± 54) 131 (± 72) 0.062 0.038 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.012; Levene p=0.761
Bilirrubine (mg/dL) 1.05 (± 0.63) Spearman ρ=0.00; p=0.983 1.10 (± 0.82) 1.11 (± 0.59) 0.86 (± 0.48) 0.490 0.983 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.687
1 month (Labs) — Overall n=28 | group ns: 14/12/2
Hemoglobine (g/dL) 13.6 (± 1.7) Pearson r=-0.27 [-0.61, 0.15]; p=0.195 13.7 (± 0.5) 12.9 (± 1.8) 13.3 (± 4.2) 0.300 0.195 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.083; Levene p=0.002
Platelets (x 103/mm3) 181 (± 56) Pearson r=-0.36 [-0.67, 0.05]; p=0.086 203 (± 71) 166 (± 40) 146 (± 35) 0.229 0.086 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.950; Levene p=0.113
Creatinine (mg/dL) 1.39 (± 1.21) Spearman ρ=0.39; p=0.052 1.03 (± 0.34) 1.87 (± 1.86) 1.20 (± 0.14) 0.080 0.052 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.440
NT-proBNP (pg/ml) 1494 (980-3628) Spearman ρ=0.11; p=0.600 1186 (838-3016) 2050 (1314-3888) 1687 (1334-2040) 0.614 0.600 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.624
Alkaline Phosphatase (IU/L) 88 (± 38) Pearson r=-0.23 [-0.58, 0.21]; p=0.300 91 (± 45) 84 (± 36) 84 (± 50) 0.920 0.300 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.777; Levene p=0.723
ALT (IU/L) 23 (± 14) Spearman ρ=0.17; p=0.409 18 (± 9) 29 (± 19) 28 (± 11) 0.130 0.409 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.007; Levene p=0.294
AST (IU/L) 28 (± 8) Pearson r=0.00 [-0.39, 0.40]; p=0.991 26 (± 7) 27 (± 10) 30 (± 9) 0.807 0.991 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.939; Levene p=0.779
GGT (IU/L) 79 (± 87) Spearman ρ=0.20; p=0.341 45 (± 38) 116 (± 125) 84 (± 71) 0.099 0.341 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.257
Bilirrubine (mg/dL) 0.96 (± 0.40) Spearman ρ=-0.07; p=0.723 0.97 (± 0.44) 1.03 (± 0.43) 0.70 (± 0.14) 0.615 0.723 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.013; Levene p=0.577
12 months (Labs) — Overall n=17 | group ns: 9/7/1
Hemoglobine (g/dL) 14.0 (± 1.0) Pearson r=0.07 [-0.44, 0.54]; p=0.804 13.8 (± 0.9) 13.8 (± 1.0) 14.4 (± NA) 0.818 0.804 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.833; Levene p=0.573
Platelets (x 103/mm3) 178 (± 50) Pearson r=-0.12 [-0.58, 0.40]; p=0.662 175 (± 65) 194 (± 38) 144 (± NA) 0.628 0.662 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.521; Levene p=0.146
Creatinine (mg/dL) 1.23 (± 0.45) Pearson r=0.23 [-0.30, 0.65]; p=0.395 1.12 (± 0.34) 1.37 (± 0.63) 1.50 (± NA) 0.568 0.395 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.425; Levene p=0.332
NT-proBNP (pg/ml) 1310 (807-2470) Spearman ρ=-0.24; p=0.370 2406 (1828-3265) 903 (774-1205) 4776 (4776-4776) 0.008 0.370 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.100; Levene p=0.101
Alkaline Phosphatase (IU/L) 99 (± 35) Pearson r=0.15 [-0.38, 0.60]; p=0.585 95 (± 41) 87 (± 24) 111 (± NA) 0.778 0.585 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.587; Levene p=0.364
ALT (IU/L) 22 (± 13) Spearman ρ=0.26; p=0.329 22 (± 18) 21 (± 8) 26 (± NA) 0.296 0.329 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.696
AST (IU/L) 26 (± 13) Spearman ρ=0.34; p=0.203 25 (± 17) 26 (± 11) 42 (± NA) 0.392 0.203 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.815
GGT (IU/L) 94 (± 86) Spearman ρ=0.42; p=0.109 82 (± 123) 95 (± 57) 130 (± NA) 0.271 0.109 Kruskal–Wallis Shapiro–Wilk (residuals); Levene (median) Shapiro p=<0.001; Levene p=0.775
Bilirrubine (mg/dL) 0.94 (± 0.28) Pearson r=0.45 [-0.06, 0.77]; p=0.080 0.84 (± 0.19) 0.91 (± 0.16) 1.20 (± NA) 0.182 0.080 ANOVA Shapiro–Wilk (residuals); Levene (median) Shapiro p=0.682; Levene p=0.586
1 Continuous association: Pearson if both pass Shapiro (p>0.05), else Spearman. Binary rows: t-test if residual normality + Levene OK, else Wilcoxon.
2 Group comparison: continuous → ANOVA if Shapiro(residuals) & Levene OK, else Kruskal–Wallis; binary → Chi-squared if all expected ≥5, else Fisher’s exact.